229
Views
3
CrossRef citations to date
0
Altmetric
ARTICLE

Pilot Study of Human Recombinant Hyaluronidase–Enhanced Subcutaneous Hydration and Opioid Administration for Sickle Cell Disease Acute Pain Episodes

, , , &
Pages 10-18 | Received 26 Sep 2012, Accepted 17 Dec 2012, Published online: 25 Mar 2013

REFERENCES

  • Lanzkron S, Carroll CP, Haywood C Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol. 2010;85:797–799.
  • Yusuf HR, Atrash HK, Grosse SD, Parker CS, Grant AM. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999–2007. Am J Prev Med. 2010;38(4 Suppl):S536–S541.
  • Benjamin LJ, Dampier CD, Jacox AK, Guideline for the Management of Acute and Chronic Pain in Sickle-Cell Disease. APS Clinical Practice Guidelines Series, No. 1. Glenview, IL: American Pain Society; 1999.
  • National Institutes of Health. The Management of Sickle Cell Disease. 4th ed. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources; 2002. NIH Publication No. 02-2117.
  • Silbergleit R, Jancis MO, McNamara RM. Management of sickle cell pain crisis in the emergency department at teaching hospitals. J Emerg Med. 1999;17:625–630.
  • Solomon LR. Pain management in adults with sickle cell disease in a medical center emergency department. J Natl Med Assoc. 2010;102:1025–1032.
  • Tanabe P, Myers R, Zosel A, Emergency department management of acute pain episodes in sickle cell disease. Acad Emerg Med. 2007;14:419–425.
  • Brannam L, Blaivas M, Lyon M, Flake M. Emergency nurses’ utilization of ultrasound guidance for placement of peripheral intravenous lines in difficult-access patients. Acad Emerg Med. 2004;11:1361–1363.
  • Panebianco NL, Fredette JM, Szyld D, Sagalyn EB, Pines JM, Dean AJ. What you see (sonographically) is what you get: vein and patient characteristics associated with successful ultrasound-guided peripheral intravenous placement in patients with difficult access. Acad Emerg Med. 2009;16:1298–1303.
  • Dargin JM, Rebholz CM, Lowenstein RA, Mitchell PM, Feldman JA. Ultrasonography-guided peripheral intravenous catheter survival in ED patients with difficult access. Am J Emerg Med. 2010;28:1–7.
  • Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4:427–440.
  • Duthie ES, Chain EA. A mucolytic enzyme in testes extracts. Nature. 1939;144:977–978.
  • Bookbinder LH, Hofer A, Haller MF, A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006;114:230–241.
  • Halozyme Therapeutics, Inc. Hylenex recombinant (hyaluronidase human injection) prescribing information. San Diego, CA: Halozyme Therapeutics, Inc.; 2012.
  • Spandorfer PR. Subcutaneous rehydration: updating a traditional technique. Pediatr Emerg Care. 2011;27:230–236.
  • Thomas JR, Yocum RC, Haller MF, Flament J. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers. J Pain Symptom Manage. 2009;38:673–682.
  • Thomas JR, Wallace MS, Yocum RC, Vaughn DE, Haller MF, Flament J. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage. 2009;38:663–672.
  • Dychter SS, Ebel D, Mead TR, Yocum RC. Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + Lactated Ringer's solution administered subcutaneously: a phase IV, double-blind, randomized pilot study in healthy volunteers. Curr Ther Res. 2009;70:421–438.
  • Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med. 2007;10:1312–1320.
  • Pirrello RD, Chen CT, Thomas SH. Initial experiences with subcutaneous recombinant human hyaluronidase. J Palliat Med. 2007;10:861–864.
  • Ramsay MAE, Savege TM, Simpson BRJ, Goodwin R. Controlled sedation with alphaxalone-alphadolone. BMJ. 1974;2:656–659.
  • Haynes J, Allison RC. Pulmonary edema: complication in the management of sickle cell crisis. Am J Med. 1986;80: 833–840.
  • Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010;26:279–288.
  • Muchmore DB, Vaughn DE. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Technol. 2010;4:419–428.
  • Spandorfer PR, Mace SE, Okada PJ, A randomized clinical trial of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in mild to moderately dehydrated children in the emergency department. Clin Ther. 2012;34:2232–2245.
  • Gonzalez ER, Ornato JP, Ware D, Bull D, Evens RP. Comparison of intramuscular analgesic activity of butorphanol and morphine in patients with sickle cell disease. Ann Emerg Med. 1988;17:788–791.
  • Uzun B, Kekec Z, Gurkan E. Efficacy of tramadol vs meperidine in vasooclusive sickle cell crisis. Am J Emerg Med. 2010;28:445–449.
  • Dampier CD, Setty BN, Logan J, Ioli JG, Dean R. Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. J Pediatr. 1995;126:461–467.
  • van Beers EJ, van Tuijn CFJ, Nieuwkerk PT, Friederich PW, Vranken JH, Biemond BJ. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol. 2007;82:955–960.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.